The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Preclinical analysis and clinical validation to identify biomarkers of regorafenib efficacy in patients with metastatic colorectal cancer.
 
Mitsukuni Suenaga
Honoraria - Daiichi Sankyo; Lilly Japan; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Tetsuo Mashima
No Relationships to Disclose
 
Naomi Kawata
No Relationships to Disclose
 
Shingo Dan
No Relationships to Disclose
 
Hiroyuki Seimiya
Stock and Other Ownership Interests - MiRTeL
Honoraria - Takeda
Research Funding - Fujifilm; Takeda
Patents, Royalties, Other Intellectual Property - Patent #6853789; Patent #6899848; Patent #6923138
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)